Qingfeng Du Selected Research

BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

7/2015	A comparative proteomic study of Homoharringtonine-induced apoptosis in leukemia K562 cells.
6/2012	[Identification of differentially expressed genes related to blastic crisis in chronic myeloid leukemia].
9/2010	The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia.
12/2002	[The application of dual fusion interphase fluorescence in situ hybridization probe in detecting minimal residual disease in chronic myeloid leukemia].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qingfeng Du Research Topics

Disease

4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2015 - 12/2002
3	Neoplasms (Cancer) 01/2024 - 11/2018
3	Hepatocellular Carcinoma (Hepatoma) 01/2024 - 09/2023
2	Inflammation (Inflammations) 04/2024 - 12/2022
1	Cognitive Dysfunction 04/2024
1	Neoplasm Metastasis (Metastasis) 09/2023
1	Heart Failure 01/2023
1	Cardiomyopathies (Cardiomyopathy) 01/2023
1	Carcinoma (Carcinomatosis) 12/2022
1	Lead Poisoning (Poisoning, Lead) 01/2022
1	COVID-19 01/2021
1	Premature Birth (Birth, Premature) 12/2019
1	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 01/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Dysbiosis 01/2019
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2018
1	Myeloid Leukemia (Leukemia, Myelocytic) 11/2018
1	Carcinogenesis 11/2018
1	Hemorrhage 10/2016
1	Leukemia 07/2015
1	Thalassemia 06/2014
1	Aplastic Anemia (Anemia, Hypoplastic) 06/2014
1	Graft vs Host Disease (Graft-Versus-Host Disease) 06/2014
1	Hematologic Diseases (Blood Diseases) 06/2014
1	Blast Crisis (Blast Phase) 06/2012
1	Disease Progression 06/2012
1	Residual Neoplasm 12/2002

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 09/2023 - 07/2015
2	Particulate MatterIBA 12/2019 - 01/2019
1	AdiponectinIBA 04/2024
1	Insulin (Novolin)FDA Link 04/2024
1	icaritinIBA 01/2024
1	celastrolIBA 11/2023
1	Liposomes (Liposome)IBA 11/2023
1	baicalinIBA 09/2023
1	CateninsIBA 09/2023
1	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2023
1	Aristolochic AcidsIBA 12/2022
1	CytokinesIBA 12/2022
1	AcidsIBA 01/2022
1	Air Pollutants (Pollutants, Air)IBA 01/2021
1	6-mercapto-1-hexanolIBA 01/2019
1	geranylgeraniol monophosphateIBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2018
1	EphB4 ReceptorIBA 11/2018
1	EphrinsIBA 11/2018
1	HomoharringtonineIBA 07/2015
1	HLA Antigens (Human Leukocyte Antigens)IBA 06/2014
1	Methotrexate (Mexate)FDA LinkGeneric 06/2014
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 06/2014
1	Galectin 3 (LGALS3)IBA 06/2012
1	Biomarkers (Surrogate Marker)IBA 06/2012
1	Transcription Factors (Transcription Factor)IBA 06/2012
1	Heterogeneous-Nuclear Ribonucleoprotein KIBA 09/2010

Therapy/Procedure

2	Therapeutics 01/2024 - 06/2014
1	Sutures (Suture) 10/2016
1	Stem Cell Transplantation 06/2014
1	Aftercare (After-Treatment) 12/2002